Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity
about
Interaction between Tat and Drugs of Abuse during HIV-1 Infection and Central Nervous System DiseaseNegative elongation factor is required for the maintenance of proviral latency but does not induce promoter-proximal pausing of RNA polymerase II on the HIV long terminal repeat.Combinatorial latency reactivation for HIV-1 subtypes and variantsThe effects of opioids on HIV reactivation in latently-infected T-lymphoblasts.The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.Genetic selection for context-dependent stochastic phenotypes: Sp1 and TATA mutations increase phenotypic noise in HIV-1 gene expression.COMMD1/Murr1 reinforces HIV-1 latent infection through IκB-α stabilizationp53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation.The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat.A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy.tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection.Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signaturesDeployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic developmentMapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise.Control of HIV latency by epigenetic and non-epigenetic mechanisms.Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.Making a Short Story Long: Regulation of P-TEFb and HIV-1 Transcriptional Elongation in CD4+ T Lymphocytes and Macrophages.Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.Didehydro-Cortistatin A: a new player in HIV-therapy?Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter.HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations.The viral protein Tat can inhibit the establishment of HIV-1 latency.Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia.Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.Identification of benzazole compounds that induce HIV-1 transcription.Assays for precise quantification of total (including short) and elongated HIV-1 transcripts.Combining Cell and Gene Therapy in an Effort to Eradicate HIV.Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.Mechanisms of HIV Transcriptional Regulation and Their Contribution to LatencyHIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.
P2860
Q26770397-B5533647-B007-402C-BAF9-D915385C4216Q33602605-A7435202-8FF1-4467-B3F5-72B37D5F1ED1Q33877492-D73237AF-E509-4EC7-9489-740A162E0CFCQ33880531-0A287AB5-5B70-455C-9F6E-19F4CEC9A874Q34544409-89F8BDFB-4FC5-4DFA-9E98-17CF36DDB08AQ34845153-922A2047-380A-4C47-BAB3-DF9FDF4543C1Q35076655-5127629A-AB4A-44D0-A8D1-252E8BDA6E32Q35641069-00B255EC-28B4-43D9-BD62-AB849E4D10C6Q35829282-BCA314E7-A0C7-47D7-9DE9-253DF5B41EDCQ36609063-68242259-FA82-4AEE-8349-06EA7906A658Q36736780-9A2BCCBD-D5F1-421D-B165-C318586811FBQ36827396-83128B33-AE50-4742-95F6-7744B927E747Q36867198-3DA3A6D8-26A6-4F42-BD9D-C35C9F24CF94Q37127522-8CE419B4-F63D-48AB-8839-9A8CD7DB5523Q37822089-09379E2F-504B-4F39-9DA1-8DB51B83BD06Q37972643-619EDC1A-0C93-4679-AFD7-DF1FF028D0A6Q37972644-8FA28399-E931-4E8B-B73C-F760E23DD69FQ38078562-EC74FBF5-C8EE-4C87-AE93-12A8D05ED801Q38212042-C1D6A44F-2850-4801-9C03-1289F4E30714Q38430337-16FA85D4-AC3D-4EB9-82C2-66F4A98EC915Q38440932-FB7B61A4-DFFD-4800-98C3-FEC7B200FEDBQ38591360-9D2CF91D-AFFF-46B2-AC6D-1B07E3ABE6D7Q39134277-D001579B-396E-4345-9E02-45AC05756C76Q39413458-3E0A9C28-7550-4352-B5C9-F02D78C8FDFBQ39619066-74AF879D-0C64-4090-8854-281B82BD54CDQ39712159-38FE3BE3-AA97-466B-A844-B10C6069814FQ40154908-0C411E4D-B9EC-4363-8207-7917035F902AQ40391119-86DA9B67-2FB3-4F30-9406-672F4646D5A5Q40427938-E939F523-D3E0-4E02-B657-1E8F5E9989BBQ41760939-5216FD63-CD4C-45AE-BAF1-B7A21C5CC055Q41769072-F2484F67-7AC8-46FA-AABA-C06915D2AA0DQ52680785-A4CE61D7-67E3-4879-A453-7AB404521B5F
P2860
Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Latently-infected CD4+ T cells ...... aired transactivation activity
@ast
Latently-infected CD4+ T cells ...... aired transactivation activity
@en
type
label
Latently-infected CD4+ T cells ...... aired transactivation activity
@ast
Latently-infected CD4+ T cells ...... aired transactivation activity
@en
prefLabel
Latently-infected CD4+ T cells ...... aired transactivation activity
@ast
Latently-infected CD4+ T cells ...... aired transactivation activity
@en
P2093
P2860
P50
P1433
P1476
Latently-infected CD4+ T cells ...... aired transactivation activity
@en
P2093
Chris Ahlgren
Douglas Richman
Joseph K Wong
Karen Chang
Matthew Strain
Steven Yukl
Susan Little
William Pasutti
P2860
P304
P356
10.1016/J.VIROL.2009.01.013
P407
P577
2009-03-05T00:00:00Z